A $65.9 million gain from a business sale largely drove Health Catalyst's $40.5 million profit.
Health Catalyst (HCAT) reported Q3 2026 revenue of $56.3M, down 26% YoY, but net income of $40.5M, driven by a $65.9M gain from a business sale. The company reaffirmed its full-year revenue guidance of $246M-$249M and Adjusted EBITDA of $18M-$18.5M. Management focuses on client retention and profitable revenue growth.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh profit numbers and guidance, offering traders a basis for short‑term positioning.
Market read
First‑report quarterly earnings with unexpected profit could move HCAT stock in after‑hours trading.
What to watch
Guidance reaffirmation and adjusted EBITDA guidance remain modest, indicating limited growth.
Background
Health Catalyst is a Nasdaq‑listed healthcare intelligence firm that provides data‑analytics platforms to health systems.
Ticker impact
Health Catalyst reported Q3 results with a $40.5M profit driven by a $65.9M gain from a business sale.
potential upside as market prices in better-than-expected profit
First‑report earnings release with positive net income and guidance reaffirmation.
Market effects
May influence other healthcare‑technology stocks as earnings beat shows profitability path.
Limited to U.S. healthcare data‑analytics niche.
Low; primarily a company‑specific event.
Counterpoint
Profit driven by one-time sale may not be sustainable; revenue decline could pressure the stock.
Key entities
- ExecutiveSimeon Kohl
President and CEO of Health Catalyst, quoted in the release.




